Learn More
Background: Long-term follow-up on a clinical trial of 15 stage III-IV NSCLC patients treated with an Indoleamine 2,3-Dioxygenase (IDO) peptide vaccine (NCT01219348). Methods: Fifteen HLA-A2-positive(More)
Methods In order to characterize the long term fate of the infused tumor-reactive TILs and their attributes, we performed a longitudinal multidimension analysis of samples from 28 patients with(More)
  • 1